Factor Xa Inhibitor-Related Intracranial Hemorrhage
Panos N, Cook A, John S, Jones G, Kelly H, Choi R, Kalaria N, Rosini J, Jones M, Rehman M, Ross P, Motley B, Delibert S, George B, Andrews C, Neyens R, Martin R, Schomer K, Armahizer M, Pajoumand M, May C, Smetana K, Strohm T, Hamm C, Jakubowski L, Keegan S, Srinivasan V, Burdick C, Martinez O, Bahrassa F, May S, Sowers K, Lin E, Rohaley D, Mackey J, Wetmore L, Frick C, Thatikunta M, Urben L, Ammar A, Owusu K, Nguyen K, Erdman M, Gilbert B, DeMott J, Peksa G, Tobias P, Da Silva I, Mahmoud L, Sheahan B, Gennaro A, Pizzi M, Brophy G, Rivet D, Strein M, Arandela K, Hellerslia V, Caylor M. Factor Xa Inhibitor-Related Intracranial Hemorrhage. Circulation 2020, 141: 1681-1689. PMID: 32264698, DOI: 10.1161/circulationaha.120.045769.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood Coagulation FactorsFactor Xa InhibitorsFemaleHematoma, SubduralHemostasisHemostaticsHospital MortalityHumansIntracranial ThrombosisLength of StayMaleMiddle AgedPyrazolesPyridonesRetrospective StudiesRisk FactorsRivaroxabanSubarachnoid HemorrhageTime FactorsTreatment OutcomeUnited StatesConceptsProthrombin complex concentrateInfusion-related reactionsIntracranial hemorrhageFactor Xa inhibitorsPCC administrationGood hemostasisHospital mortalityThrombotic eventsXa inhibitorsEfficacy of PCCHemostatic efficacyMedian intensive care unitAdministration of PCCOral factor Xa inhibitorsPrimary efficacy outcomeThrombotic event occurrencesObservational cohort studyPercentage of patientsIntensive care unitLength of stayPrimary analysis groupHospital lengthEfficacy outcomesHospital dischargeSecondary outcomes